Sanofi's Cablivi, or caplacizumab-yhdp, has been approved by the FDA for use in combination with plasma exchange and immunosuppression as a treatment for adult patients with acquired thrombotic thrombocytopenic purpura.
Sanofi's drug for rare low platelet disorder approved by FDA
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.